0001209191-20-049578.txt : 20200903
0001209191-20-049578.hdr.sgml : 20200903
20200903214752
ACCESSION NUMBER: 0001209191-20-049578
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200828
FILED AS OF DATE: 20200903
DATE AS OF CHANGE: 20200903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CLARKE JOHN K
CENTRAL INDEX KEY: 0001219015
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37378
FILM NUMBER: 201160522
MAIL ADDRESS:
STREET 1: C/O CARDINAL HEALTH PARTNERS
STREET 2: 221 NASSAU STREET
CITY: PRINCETON
STATE: NJ
ZIP: 08542
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: aTYR PHARMA INC
CENTRAL INDEX KEY: 0001339970
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203435077
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-731-8389
MAIL ADDRESS:
STREET 1: 3545 JOHN HOPKINS COURT, STE #250
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-28
0
0001339970
aTYR PHARMA INC
LIFE
0001219015
CLARKE JOHN K
3545 JOHN HOPKINS COURT, SUITE #250
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2020-08-28
4
S
0
100
4.00
D
117843
I
See Footnote
Common Stock
2020-09-02
4
S
0
7260
4.01
D
110583
I
See Footnote
Common Stock
7492
D
There shares are owned directly by CHP II, LLP ("CHP"). The general partner of CHP is CHP II Management, LLC, ("CHP Management"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Nancy Denyes, Attorney-in-Fact
2020-09-03